Since there are so very few Indian stocks trading on the U.S. exchanges, most of the well known names have been on my radar for years. One such example is Dr. Reddy's Laboratories (RDY), which I've had on various watch lists for years on end but never once bought. [Nov 9, 2009: Dr. Reddy's Laboratories Impressive on Both Fundamental and Technical Basis] As I am scanning to see what is performing on a day like today (where breadth is actually quite poor), this stock is shining. In fact, it's at a 52-week high. I can find no particular news to drive it today and, indeed, its last earnings report a month ago was OK but no great shakes. It is well over 20x forward estimates and analysts actually dropped EPS for "2010" (year ends March 11) by 20 cents, from $1.57 to $1.37. But for whatever reason (perhaps the launch of quite a few drugs in the future) the market likes the name.
Established in 1984, Dr. Reddy's Laboratories is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection.
While the close is more important than the intraday action as I type the stock looks to be breaking over early April 10 highs. (Click to enlarge)
May's commentary on earnings report via Reuters:
- India's Dr. Reddy's Laboratories lagged analyst expectations in quarterly profit, but expects the launch of more than a dozen new drugs in the United States to boost growth in this financial year.
- "We are planning to launch 12 to 13 products this year in the United States, and some of them will be very significant," Prasad told Reuters in a telephone interview from the company's headquarters in southern city of Hyderabad.
- Chief Executive G.V. Prasad said a pick-up in sales of omeprazole, a generic version of AstraZeneca's (AZN) Prilosec, in the months ahead was also expected to underpin growth in the year that began on April 1.
- The Indian generics business boom has lured Western drug makers that want to raise exposure in fast-growing emerging markets where a burgeoning middle class wants the assurance of cheap, safe drugs.
- The New York-listed company reported a net profit of 1.7 billion rupees ($37 million) in the quarter to March, its fiscal fourth quarter, compared with a loss of 9.8 billion in the year-ago period.
- Revenue fell 18% to 16.4 billion rupees, as sales in the United States, its biggest export market, nearly halved to 3.5 billion and European revenue declined by a third to 2.1 billion.
Disclosure: No position